Sucampo Pharmaceuticals, Inc.(Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that theUnited Kingdom's National Institute of Health and Care Excellence (NICE) has released a Final Appraisal Determination with guidance for the recommendation of the use of Amitiza (lubiprostone) in the treatment of chronic idiopathic constipation and associated symptoms in adults who have failed laxatives.

This guidance by NICE's appraisal committee recommends lubiprostone as an option for the treatment of patients who are considered to be the most difficult to treat, having failed at least two previous laxatives at maximum tolerated doses for a period of six months, and for whom invasive procedures are being considered.

For more details, go to: http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-newsArticle&ID=1940632&highlight=